Form 4: GTHP Director Imhoff Boosts Stake via Conversions, Warrant Exercises

GUIDED THERAPEUTICS Director John E. Imhoff significantly increased his beneficial ownership in the company through multiple conversions of debt and preferred stock into common shares and warrant exercises.

Summary

• John E. Imhoff, a Director and 10% owner of GUIDED THERAPEUTICS INC (GTHP), reported multiple transactions increasing his direct beneficial ownership of common stock.
• On December 18, 2025, Imhoff converted $13,682.19 from a Convertible Promissory Note (dated September 25, 2025) into 195,460 shares of common stock at $0.07 per share.
• On January 5, 2026, 25,338 shares of common stock were issued to Imhoff for accrued dividends on his Series E preferred stock at a conversion price of $0.3157.
• On February 2, 2026, Imhoff converted an additional $21,890.41 from the same Convertible Promissory Note into 312,720 shares of common stock at $0.07 per share.
• During February 2026, Imhoff exchanged 500,000 warrants with an exercise price of $0.50 for 500,000 warrants with an exercise price of $0.20, subsequently exercising the new warrants for $100,000.
• The expiration date of 500,000 warrants with an exercise price of $0.65 was extended for one year to September 1, 2027, in connection with the exchange agreement.
• On February 27, 2026, Imhoff converted 100 shares of Series E preferred stock (stated value $1,000, $0.25 conversion price) into 400,000 shares of common stock.
• Also on February 27, 2026, Imhoff converted $10,926.03 from the Convertible Promissory Note into 156,086 shares of common stock at $0.07 per share.
• Following these transactions, Imhoff's direct beneficial ownership of common stock increased from 19,658,955 shares to 21,053,099 shares.
• A total of $120,000 principal remains outstanding under the September 25, 2025 Convertible Promissory Note, which has a variable conversion price upon an event of default.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive. While the conversions and exercises lead to dilution, the significant increase in a director's direct common stock ownership, coupled with the cash infusion from warrant exercises, signals strong insider confidence and a reduction in certain liabilities.

Positives

• John E. Imhoff, a Director and 10% owner, significantly increased his direct beneficial ownership of common stock, indicating strong insider confidence.
• Conversions of debt and preferred stock into common equity reduce the company's outstanding liabilities and preferred obligations.
• The exercise of warrants at $0.20 per share generated $100,000 in cash for the company.
• The conversion prices of $0.07 for the promissory notes and $0.25 for the Series E preferred stock are relatively low, suggesting favorable terms for the insider.

Negatives

• The conversions of promissory notes and preferred stock, along with warrant exercises, result in dilution of existing common shareholders.
• The remaining $120,000 principal on the Convertible Promissory Note has a variable conversion price upon an event of default, which could lead to significant dilution if the company faces financial distress.
• The extension of warrant expiration dates could prolong potential future dilution.

Risks

• The remaining $120,000 principal under the September 25, 2025 Convertible Promissory Note is convertible into common stock at a variable conversion price upon an event of default, posing a risk of significant dilution to existing shareholders if such an event occurs.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant insider buying or conversions, especially by a director and 10% owner, can often be interpreted by the market as a signal of confidence in the company's future prospects, even if it involves debt-to-equity conversions.

Related Party Transactions

• Conversions of Convertible Promissory Notes held by Director John E. Imhoff into common stock.
• Issuance of common stock to John E. Imhoff for accrued dividends on his Series E preferred stock.
• Exchange and exercise of warrants by John E. Imhoff.
• Conversion of Series E preferred stock held by John E. Imhoff into common stock.

Stakeholder Impact

• Shareholders: Experience dilution due to the issuance of new common shares from debt, preferred stock, and warrant conversions. However, increased insider ownership may be seen as a positive signal of confidence.
• Creditors: The conversion of promissory notes reduces the company's outstanding debt obligations to the reporting person.

Next Steps

• The remaining $120,000 principal under the September 25, 2025 Convertible Promissory Note is still outstanding and may be converted into common stock in the future.
• The extended warrants with an exercise price of $0.65 and an expiration date of September 1, 2027, represent potential future exercises.

Key Dates

Recommendation

The significant increase in insider ownership by a director and 10% owner, through various conversions and warrant exercises, typically signals strong confidence in the company's future. However, the associated dilution from these transactions and the potential for further dilution from the remaining convertible debt with a variable conversion price upon default introduce a degree of uncertainty. The low conversion prices for debt and preferred stock are favorable for the insider but reflect a potentially low valuation. Given these mixed signals, a 'hold' recommendation is appropriate, suggesting investors monitor future developments and the company's operational performance.

Keywords

GUIDED THERAPEUTICS, GTHP, Form 4, Insider Trading, Beneficial Ownership, Common Stock, Convertible Promissory Note, Preferred Stock Conversion, Warrant Exercise, Director Transactions, Equity Dilution, Insider Confidence